Analysis of serum macrophage migration inhibitory factor and D-dopachrome tautomerase in systemic sclerosis

被引:17
|
作者
Vincent, Fabien B. [1 ]
Lin, Emily [1 ]
Sahhar, Joanne [1 ,2 ]
Ngian, Gene-Siew [1 ,2 ]
Kandane-Rathnayake, Rangi [1 ]
Mende, Rachel [1 ]
Hoi, Alberta Y. [1 ]
Morand, Eric F. [1 ,2 ]
Lang, Tali [1 ,3 ]
Harris, James [1 ]
机构
[1] Monash Univ, Monash Hlth, Sch Clin Sci, Ctr Inflammatory Dis, Clayton, Vic, Australia
[2] Monash Hlth, Dept Rheumatol, Clayton, Vic, Australia
[3] Cabrini Inst, Szalmuk Family Dept Med Oncol, Malvern, Vic 3144, Australia
基金
英国医学研究理事会;
关键词
biomarker; cytokine; systemic lupus erythematosus (SLE); systemic sclerosis; MIF; EXPRESSION; CYTOKINE; ASSOCIATION; DISEASE; TRIALS; GENE;
D O I
10.1002/cti2.1042
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives. Macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (DDT), members of the same cytokine superfamily, are linked to the pathogenesis of a number of inflammatory diseases. The aim of this study was to investigate their clinical relevance in systemic sclerosis (SSc). Methods. Serum MIF and DDT were quantified in 105 SSc patients by ELISA and levels compared to healthy controls (HC) (47) and patients with systemic lupus erythematosus (SLE) (184). Clinical parameters included organ involvement, serum laboratory markers and results of pulmonary function tests, and overall disease activity assessed using the European Scleroderma Trials and Research group (EUSTAR) activity index. Results. There was no significant difference in serum DDT concentrations between patients with SSc and HC. However, serum MIF was significantly increased in SSc compared to both HC and SLE cohorts. Serum MIF was increased in SSc patients with low forced vital capacity (FVC) and was also associated with the use of angiotensin II receptor blockers and beta blockers in SSc, confirmed after adjusting for the presence of systemic hypertension and low FVC. Serum DDT was significantly higher in SSc patients with low FEV1 and negatively correlated with EUSTAR score, particularly in patients with limited disease. Conclusion. Although not significantly linked to specific clinical parameters, serum MIF was significantly higher in SSc patients than in HC and SLE patients, suggesting a fundamental role for MIF in SSc. DDT, while closely related to MIF, did not show a similar expression profile, suggesting functional differences between these molecules.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Overexpression of Macrophage Migration Inhibitory Factor and Its Homologue D-Dopachrome Tautomerase as Negative Prognostic Factor in Neuroblastoma
    Cavalli, Eugenio
    Mazzon, Emanuela
    Mammana, Santa
    Basile, Maria Sofia
    Lombardo, Salvo Danilo
    Mangano, Katia
    Bramanti, Placido
    Nicoletti, Ferdinando
    Fagone, Paolo
    Petralia, Maria Cristina
    BRAIN SCIENCES, 2019, 9 (10)
  • [2] The macrophage migration inhibitory factor (MIF)-homologue D-dopachrome tautomerase is a therapeutic target in a murine melanoma model
    Kobold, Sebastian
    Merk, Melanie
    Hofer, Luisa
    Peters, Philip
    Bucala, Richard
    Endres, Stefan
    ONCOTARGET, 2014, 5 (01) : 103 - 107
  • [3] The Role of Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (D-DT/MIF-2) in Infections: A Clinical Perspective
    Breidung, David
    Megas, Ioannis-Fivos
    Freytag, David Lysander
    Bernhagen, Juergen
    Grieb, Gerrit
    BIOMEDICINES, 2024, 12 (01)
  • [4] Phylogeny and evolution of plant macrophage migration inhibitory factor/D-dopachrome tautomerase-like proteins
    Panstruga, Ralph
    Baumgarten, Kira
    Bernhagen, Juergen
    BMC EVOLUTIONARY BIOLOGY, 2015, 15
  • [5] Dysregulated D-dopachrome Tautomerase, a Hypoxia-inducible Factor-dependent Gene, Cooperates with Macrophage Migration Inhibitory Factor in Renal Tumorigenesis
    Pasupuleti, Vinay
    Du, Weinan
    Gupta, Yashi
    Yeh, I-Ju
    Montano, Monica
    Magi-Galuzzi, Cristina
    Welford, Scott M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (06) : 3713 - 3723
  • [6] Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (DDT): Pathways to Tumorigenesis and Therapeutic Opportunities
    Valdez, Caroline Naomi
    Sanchez-Zuno, Gabriela Athziri
    Bucala, Richard
    Tran, Thuy T.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (09)
  • [7] Plasma levels of Macrophage Migration inhibitory Factor and D-Dopachrome Tautomerase show a highly specific Profile in early life
    Roger, Thierry
    Schlapbach, Luregn J.
    Schneider, Anina
    Weier, Manuela
    Wellmann, Sven
    Marquis, Patrick
    Vermijlen, David
    Sweep, Fred C. G. J.
    Leng, Lin
    Bucala, Richard
    Calandra, Thierry
    Giannoni, Eric
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [8] Combined Knockdown of D-dopachrome Tautomerase and Migration Inhibitory Factor Inhibits the Proliferation, Migration, and Invasion in Human Cervical Cancer
    Wang, Qingying
    Wei, Yingze
    Zhang, Jiawen
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (04) : 634 - 642
  • [9] The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF)
    Merk, Melanie
    Zierow, Swen
    Leng, Lin
    Das, Rituparna
    Du, Xin
    Schulte, Wibke
    Fan, Juan
    Lue, Hongqi
    Chen, Yibang
    Xiong, Huabao
    Chagnon, Frederic
    Bernhagen, Juergen
    Lolis, Elias
    Mor, Gil
    Lesur, Olivier
    Bucala, Richard
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (34) : E577 - E585
  • [10] D-dopachrome tautomerase is over-expressed in pancreatic ductal adenocarcinoma and acts cooperatively with macrophage migration inhibitory factor to promote cancer growth
    Guo, Dawei
    Guo, Jinshuai
    Yao, Junchao
    Jiang, Kun
    Hu, Jianhua
    Wang, Bo
    Liu, Haiyang
    Lin, Lin
    Sun, Wenyu
    Jiang, Xiaofeng
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (09) : 2056 - 2067